Morepen Laboratories Files First ANDA for Sitagliptin Tablets with USFDA

Morepen Laboratories has entered a new phase in its pharmaceutical offerings by submitting its first Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (USFDA) for Sitagliptin Tablets USP. The application covers three dosage strengths: 25 mg, 50 mg, and 100 mg. This milestone marks Morepen's expansion from primarily Active Pharmaceutical Ingredient (API) production and Contract Development and Manufacturing Organization (CDMO) services into integrated finished dosage formulation and regulatory filings.

The Sitagliptin project involved a comprehensive set of activities essential for successful drug development and regulatory approval. These include formulation development and scale-up processes, along with the development and validation of analytical methods to ensure quality and consistency. Managing impurities and conducting stability studies were also key components to satisfy Good Manufacturing Practice (GMP) standards during production of regulatory batches.

Additionally, Morepen Laboratories incorporated a bioequivalence strategy, which is crucial for generic drug approval by demonstrating therapeutic equivalence to the reference brand. Coordination with contract research organizations (CROs) was part of the process to carry out necessary clinical studies. The company also integrated all development and clinical data into a comprehensive regulatory dossier for submission.

This submission enhances Morepen's capacity to undertake specialized CDMO assignments by offering end-to-end services, covering everything from API development to finished dosage formulation and regulatory compliance. It broadens the company’s ability to manage more complex and varied customer projects within the pharmaceutical development lifecycle.

Morepen anticipates a review period of approximately 24 to 36 months from the date of ANDA submission until potential approval and commercial launch. This timeline depends on the USFDA’s review process, successful inspections of the formulation facilities, and any patent or exclusivity considerations that may apply.

The pharmaceutical industry in the United States is highly regulated, with the ANDA pathway designed to expedite the availability of lower-cost generic medications while maintaining strict quality standards. Sitagliptin, a widely prescribed medication for managing type 2 diabetes, represents a significant market opportunity for generic manufacturers due to its established clinical use and demand.

Morepen Laboratories has been steadily growing as a player in pharmaceutical manufacturing and CDMO services. Its move into finished dosage development and regulatory submissions reflects broader industry trends where companies seek to provide integrated solutions, reducing development timelines and improving customer service. The company’s capabilities in analytical method validation, impurity control, and bioequivalence testing position it well to meet evolving client needs.

By advancing this ANDA submission, Morepen signals its commitment to expanding its product portfolio and enhancing its role in the pharmaceutical supply chain. If approved, its Sitagliptin tablets will offer additional options for patients and healthcare providers in the US market, supporting treatment of diabetes with a cost-effective alternative.

Overall, this development is a strategic step in Morepen Laboratories’ growth trajectory, aligning with global trends toward accessible generic medicines and comprehensive CDMO services that encompass formulation, manufacturing, and regulatory expertise.